Evidence-based Medicine
Study Commentary: Hydroxychloroquine Fails First Meaningful RCT
17 Apr, 2020 | 02:25h | UTCHydroxychloroquine fails first meaningful RCT – PulmCrit
Original Study: Hydroxychloroquine for Covid-19: No Benefit in New Open-label, Randomized Trial
Related Commentary: Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base – The Lancet Respiratory Medicine
Richard Lehman’s Covid-19 Reviews
14 Apr, 2020 | 02:46h | UTCRichard Lehman’s covid-19 reviews—13 April 2020 – The BMJ Opinion
“In this weekly round-up, Richard Lehman looks at a personal selection of articles of relevance to clinicians dealing with covid-19.”
Trials of Drugs to Prevent Coronavirus infection Begin in Health Care Workers
9 Apr, 2020 | 03:16h | UTCTrials of drugs to prevent coronavirus infection begin in health care workers – Science
Systematic Review: Prediction Models for Diagnosis and Prognosis of Covid-19
8 Apr, 2020 | 01:29h | UTC
Related Commentary on Twitter
The 31 #COVID19 predictive models for diagnosis and prognosis systematically reviewed: "poorly reported, at high risk of bias, and their reported performance is probably optimistic" @bmj_latest https://t.co/lb0U3nL877 @laure_wynants @MaastrichtU and collaborators #AI/ML pic.twitter.com/GSQigu1CxY
— Eric Topol (@EricTopol) April 7, 2020
COVID-19: More Opinions on Hydroxychloroquine
7 Apr, 2020 | 04:17h | UTCHydroxychloroquine Update For April 6 – Science Translational Medicine
The Debacle of Hydroxychloroquine and Azithromycin for COVID19 – Dr. John M.
Summary: wait for proper studies before prescribing.
Modelling the Models
6 Apr, 2020 | 01:32h | UTCModelling the models – CEBM University of Oxford
“Modelling the models. We reviewed 43 models indexed on PubMed, and 13 released by Imperial College to show the significant variation, lack of limitations and lack of references to each other.” (via @carlheneghan see Tweet)
Perspective: Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks
2 Apr, 2020 | 04:06h | UTC
Debate Podcast: John Ioannidis vs. Sten Vermund – Be It Resolved; We Are Making High-stakes Decisions About the COVID-19 Pandemic Without Reliable Data
31 Mar, 2020 | 04:45h | UTCRelated Video: Perspectives on the Pandemic with Dr. John Ioannidis
Related Article: Editorial by John P.A. Ioannidis: COVID-19: The Harms of Exaggerated Information and Non‐evidence‐based Measures (free study and commentaries)
The Mathematics of Predicting the Course of the Coronavirus
31 Mar, 2020 | 04:43h | UTCThe Mathematics of Predicting the Course of the Coronavirus – Wired
See also: Mathematics of life and death: How disease models shape national shutdowns and other pandemic policies – Science AND How to model a pandemic – The Conversation AND Coronavirus exposes the problems and pitfalls of modelling – The Guardian AND Systematic review and critical appraisal of prediction models for diagnosis and prognosis of COVID-19 infection – medRxiv
Must-see Video! Perspectives on the Pandemic with Dr. John Ioannidis
27 Mar, 2020 | 04:03h | UTCPerspectives on the Pandemic with Dr. John Ioannidis
Related Article: Editorial by John P.A. Ioannidis: COVID-19: The Harms of Exaggerated Information and Non‐evidence‐based Measures (free study and commentaries)
Mathematics of Life and Death: How Disease Models Shape National Shutdowns and Other Pandemic Policies
27 Mar, 2020 | 04:01h | UTCSee also: How to model a pandemic – The Conversation AND Coronavirus exposes the problems and pitfalls of modelling – The Guardian
Perspective: When Science Needs Self-Correcting
27 Mar, 2020 | 03:36h | UTCWhen Science Needs Self-Correcting – Medium (free)
“Admitting scientific errors is hard. It’s also important.”
Hydroxychloroquine: Small Study Shows No Benefit
26 Mar, 2020 | 01:39h | UTCCommentary: Chloroquine Use For COVID-19 Shows No Benefit In First Small—But Limited—Controlled Trial – Forbes
Related: Coronavirus treatment hype can lead to harm – Lown Institute AND No, These Medicines Cannot Cure Coronavirus – The New York times
See also: Chloroquine for COVID-19: Cutting Through the Hype
Chloroquine for COVID-19: Cutting Through the Hype
24 Mar, 2020 | 11:32h | UTCChloroquine for COVID-19: Cutting Through the Hype – The Scientist
CEBM Estimates Infection Rate Fatality (IFR) of COVID-19 at 0,20%
23 Mar, 2020 | 01:16h | UTCGlobal Covid-19 Case Fatality Rates – Centre for Evidence-Based Medicine, University of Oxford (free)
Editorial by John P.A. Ioannidis: COVID-19: The Harms of Exaggerated Information and Non‐evidence‐based Measures
23 Mar, 2020 | 01:08h | UTCRelated Opinion Piece: A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data – STAT (free)
Rebuttal 1: We know enough now to act decisively against Covid-19. Social distancing is a good place to start – STAT (free)
Rebuttal 2: A Rebuttal to “A Fiasco in the Making?” – Hilda Bastian (Free)
New Preliminary Studies with Hydroxychloroquine:
20 Mar, 2020 | 10:57h | UTCThis was an open-label study with only 42 patients without patient-relevant endpoints. The 6 patients that received Hydroxychloroquine + Azithromycin achieved more efficient virus elimination than control patients.
New in Vitro Study: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro – Cell Discovery (free)
Related Articles: In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – Clinical Infectious Diseases (free PDF) AND New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? – International Journal of Antimicrobial Agents (free) AND A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 – Journal of Critical Care (free) AND Of chloroquine and COVID-19 – Antiviral Research (free)
Calculating the Sample Size Required for Developing a Clinical Prediction Model
19 Mar, 2020 | 10:42h | UTCCalculating the sample size required for developing a clinical prediction model – The BMJ (free)
Ten Simple Rules to Becoming a Principal Investigator
8 Mar, 2020 | 20:37h | UTCTen Simple Rules to becoming a principal investigator – PLOS Computational Biology (free)
Related Commentary on Twitter
Read this article if you are wondering what is wrong in academia.
Spoiler: research integrity didn't make the 10 most important rules for becoming a PIhttps://t.co/BjhuaFuJGb pic.twitter.com/IJxBmouIBd
— Maarten van Smeden (@MaartenvSmeden) March 6, 2020
Validation and Utility Testing of Clinical Prediction Models: Time to Change the Approach
6 Mar, 2020 | 10:18h | UTCValidation and Utility Testing of Clinical Prediction Models: Time to Change the Approach – JAMA (free for a limited period)
Alex Nowbar’s journal reviews—28 February 2020
1 Mar, 2020 | 19:38h | UTCAlex Nowbar’s journal reviews, 28 February 2020 – The BMJ Opinion (free)
Alex Nowbar reviews the latest research from the top medical journals.
Related Commentary on Twitter
Turns out there is news that isn’t covid-19! New HIV approach, stuff about plasma exchange in ANCA vasculitis and the polygenic score drama Alex Nowbar's journal reviews—28 February 2020 – https://t.co/tkqiPMny5u
— Alex Nowbar (@AlexNowbar) February 29, 2020
Opinion: “WHO’s malaria vaccine study represents a “serious breach of international ethical standards””
1 Mar, 2020 | 19:04h | UTC
Opinion: The Inevitable Reimagining of Medical Education
28 Feb, 2020 | 08:30h | UTCThe Inevitable Reimagining of Medical Education – JAMA (free for a limited period)
Author Interview: The Inevitable Reimagining of Medical Education (free audio)
SPIRIT Extension and Elaboration for n-of-1 Trials: SPENT 2019 Checklist
28 Feb, 2020 | 08:27h | UTCSPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist – The BMJ (free for a limited period)
Guide to Statistics and Methods: When Can Intermediate Outcomes Be Used as Surrogate Outcomes?
28 Feb, 2020 | 08:29h | UTCWhen Can Intermediate Outcomes Be Used as Surrogate Outcomes? – JAMA (free for a limited period)